Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00402480
First received: November 21, 2006
Last updated: June 17, 2013
Last verified: November 2006

November 21, 2006
June 17, 2013
April 2003
Not Provided
Change in TCD flow velocity
Same as current
Complete list of historical versions of study NCT00402480 on ClinicalTrials.gov Archive Site
Stroke
Same as current
Not Provided
Not Provided
 
Hydroxyurea to Prevent Stroke in Children With Sickle Cell Anemia and Elevated TCD Flow Velocity
Effects of Hydroxyurea on the Prevention of Primary Stroke in Children With Sickle Cell Anemia and Elevated Transcranial Doppler (TCD) Flow Velocity

The purpose of this study is to assess prospectively the efficacy of hydroxyurea therapy in the setting of cerebrovascular disease, manifest as conditional or abnormal transcranial doppler ultrasonography (TCD) flow velocities, in children with sickle cell anemia (SCA). TCD is used to measure flow velocity in intracranial arteries as a marker of increased stroke risk in children with SCA. The primary objective of this protocol is to determine whether hydroxyurea reduces elevated TCD velocity.

The purpose of this study is to assess prospectively the efficacy of hydroxyurea therapy in the setting of cerebrovascular disease, manifest as conditional or abnormal transcranial doppler ultrasonography (TCD) flow velocities, in children with sickle cell anemia (SCA). TCD is used to measure flow velocity in intracranial arteries as a marker of increased stroke risk in children with SCA. The primary objective of this protocol is to determine whether hydroxyurea reduces elevated TCD velocity.

The STOP (Stroke Prevention in Sickle Cell Anemia) trial, a multicenter, randomized, controlled trial for primary stroke demonstrated that monthly blood transfusions, when compared to observation alone, significantly reduced the risk of primary stroke for children with SCA whose TCD velocity exceeded 200 cm/sec. Despite the STOP trial's clear results, there are unresolved issues regarding TCD and stroke risk in children with SCA. First, the predictive value of an abnormal result is not compelling since less than a third of children with an abnormal TCD velocity and even fewer with conditional results will ever develop a clinical stroke. There is also discordance between TCD and MRI results. Only 40% of children with abnormal TCD velocity will have abnormalities on brain MRI (Wang, et al. J Pediatr Hematol/Oncol 2000;22(4):335-339, Pegelow, et al. Arch Neurol 2001;58:2017-2021). There are also well recognized risks of chronic blood transfusions, including iron overload and alloimmunization, and the necessary duration of transfusion protection for children with abnormal TCD velocity is unknown. Unfortunately, there are currently no therapeutic options besides blood transfusions for patients with SCA and an abnormal TCD velocity.

Erythrocyte transfusions and hydroxyurea have many similar beneficial effects in patients with SCA. Transfusions may prevent primary stroke by lowering the % HbS, by increasing the hematocrit, by improving red cell rheology, by decreasing red cell adhesion, and by lowering TCD velocity. Hydroxyurea leads to many of the same changes, thus in this protocol, we will examine whether hydroxyurea, like transfusions, can lower TCD velocity. In our patients with SCA who have been screened with TCD ultrasonography, we have observed that children who were screened while receiving hydroxyurea had lower TCD velocity measurements than those who were not on hydroxyurea. In a small number of patients with TCD velocity measurements before and after initiation of hydroxyurea for non-neurological reasons, the TCD velocity declined significantly after achieving full dose hydroxyurea therapy. The changes in TCD velocity were correlated with changes in hematocrit since hydroxyurea increases blood counts in patients with SCA. For each % increase in hematocrit, the TCD velocity increased by 6.3 cm/sec. This was similar to an abstract from the STOP trial, in which TCD flow velocity declined by 7.9 cm/sec for each increase in % hematocrit from transfusions.

Based on this preliminary data, we initiated this prospective, single-institution, pilot trial to determine whether hydroxyurea therapy lowers TCD flow velocity in children with sickle cell anemia.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Stroke
Drug: Hydroxyurea
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
March 2006
Not Provided

Inclusion Criteria:

  • Children with Sickle Cell Anemia
  • Aged 3 to 18 years
  • Confirmed TCD velocity greater than or equal to 140cm/sec
  • Negative serum pregnancy test for subjects of childbearing potential
  • Decline transfusions (for subjects with TCD velocity greater than or equal to 200 cm/sec)
Both
3 Years to 18 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00402480
4744
Not Provided
Duke University
Duke University
Not Provided
Principal Investigator: Sherri Zimmerman, MD Duke University
Duke University
November 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP